Clinical Trial

Overfeeding Induced Fat-tissue Stimulation

Study acronym: OVID_FASTI
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 1, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Type 2 diabetes is the most common metabolic disease worldwide, characterized by hyperglycemia, decreased whole body insulin sensitivity, and white adipose tissue (WAT) dysfunction. A key factor in its development is chronic overnutrition, usually with a high-fat diet (HFD), leading to disturbances of glucose and lipid metabolism. However, the mechanism of short-term HFD-induced tissue-specific insulin resistance remains poorly understood. This project aims to further unravel the underlying mechanisms of short-term HFD overnutrition-mediated WAT insulin resistance. The model described here corresponds to a randomized, single- blinded parallel-grouped trial, consisting of two interventions: a macronutrient-balanced diet and or a hypercaloric diet over three weeks in order to investigate differences in interorgan fatty acid and glucose metabolism between the studied groups. Based on recent studies, the hypothesis is that 21-day hypercaloric HFD induces WAT insulin resistance via a diacylglycerol, novel protein kinase C-insulin receptor signaling model in both fasting and insulin-stimulated states.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-04.
Trial Details
NCT Number NCT06193668
Lead Sponsor German Diabetes Center
Collaborators: Yale University
Conditions Lipid-induced Insulin Resistance
Enrollment 32 participants
Start Date 2024-01-31
Primary Completion 2025-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-03-01